Trial Profile
An Open Label, Multicenter, Single Arm, Phase 1/2 Trial of Metronomic 5-fluorouracil in Combination With Nab-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 23 Oct 2019
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Oxaliplatin (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms FABLOx
- Sponsors Celgene Corporation
- 30 Nov 2018 Status changed from active, no longer recruiting to completed.
- 10 Sep 2018 Planned End Date changed from 31 May 2020 to 29 Oct 2018.
- 10 Sep 2018 Planned primary completion date changed from 31 May 2020 to 29 Oct 2018.